Showing 3621-3630 of 4164 results for "".
- Nanoscope Therapeutics Presents Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of RP at ARVOhttps://modernod.com/news/nanoscope-therapeutics-presents-key-results-from-phase-2b-restore-trial-of-mco-010-for-the-treatment-of-rp-at-arvo/2481583/Nanoscope Therapeutics announced the presentation of key data from its phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010 at the ARV
- Study: Low Brain Pressure Could be a Risk Factor for Developing Glaucomahttps://modernod.com/news/study-low-brain-pressure-could-be-a-risk-factor-for-developing-glaucoma/2481431/An international team of researchers led by Lithuanian scientists provide additional evidence that intracranial pressure plays an important role in normal-tension glaucoma, which accounts for up to 50 percent of all glaucoma cases. A recent clinical
- ImprimisRx Launches Fortisite (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulationhttps://modernod.com/news/imprimisrx-launches-fortisite-tobramycin-15-vancomycin-5-compounded-antibiotic-formulation/2481135/ImprimisRx announced the availability of Fortisite, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%. Compounded topical antibiotic formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-
- Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trialhttps://modernod.com/news/nicox-announces-last-patients-complete-final-visit-in-ncx-470-phase-3-mont-blanc-glaucoma-trial/2481100/Nicox announced that the last patients completed their final (3-month) visit in the Mont Blanc phase 3 clinical trial of NCX 470 0.1% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. A total of
- Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Diseasehttps://modernod.com/news/nicoxs-positive-post-hoc-results-from-ncx-4251-phase-2b-mississippi-trial-suggest-path-forward-in-dry-eye-disease/2480480/Nicox SA announced positive post hoc results from its Mississippi Phase 2b clinical trial suggesting that once-daily dosed NCX 4251, fluticasone propionate ophth
- Schwind Installs 2,000th Eye Laserhttps://modernod.com/news/schwind-installs-2000th-eye-laser/2479487/Schwind announces a milestone with the 2,000th Schwind laser system for refractive corneal surgery being installed in the Ayrshire Eye Clinic in Ayr, Scotland, by Prof. Sathish Srinivasan, founder and Medical Director
- Nova Eye: 24-Month iTrack Data Demonstrate Real-World Efficacy of Canaloplasty as Both a Standalone and Combined MIGS Procedurehttps://modernod.com/news/nova-eye-24-month-itrack-data-demonstrate-real-world-efficacy-of-canaloplasty-as-both-a-standalone-and-combined-migs-procedure/2479091/Nova Eye Medical is reporting the peer-reviewed publication of 24-month data for its proprietary iTrack minimally invasive glaucoma surgery (MIGS) technology. Published in Clinical Oph
- Systematic Review of Standalone iStent Trabecular Micro-Bypass Glaucoma Surgeryhttps://modernod.com/news/systematic-review-of-standalone-istent-trabecular-micro-bypass-glaucoma-surgery/2479056/A new meta-analysis of the iStent and iStent inject (Glaukos) found that standalone trabecular micro-bypass glaucoma surgery with the devices is associated with clinically relevant reductions in intraocular pressure. The focus of the study, which was published in the Journal of Glaucom
- Gyroscope Therapeutics Announces $148 Million Raised in Series C Financinghttps://modernod.com/news/gyroscope-therapeutics-announces-148-million-raised-in-series-c-financing/2479018/Gyroscope Therapeutics announced it has raised $148.0 million (£107.8 million) in a Series C financing. Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005,
- BJO Publishes New Data on Clearside Biomedical’s Investigational Treatment Xiperehttps://modernod.com/news/bjo-publishes-new-data-on-clearside-biomedicals-investigational-treatment-xipere/2478989/New data has been published in The British Journal of Ophthalmology related to the clinical development program of Clearside Biomedical’s Xipere, an investigational treatment with a proposed indication of macular edema associated with noninfectious uveitis.